T

Theravance Biopharma
D

TBPH

10.030
USD
-0.09
(-0.89%)
مغلق
حجم التداول
5,270
الربح لكل سهم
0
العائد الربحي
0
P/E
-9
حجم السوق
405,564,068
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALNY
    31.19
    (13.13%)
    268.66 USD
    AMGN
    2.78
    (0.84%)
    335.22 USD
    AZN
    2.040
    (2.58%)
    81.200 USD
    B
    BIIB
    -2.500
    (-1.17%)
    210.710 USD
    GILD
    0.470
    (0.62%)
    76.510 USD
    G
    GLPG
    0.270
    (1.01%)
    26.970 USD
    GSK
    0.865
    (2.23%)
    39.650 USD
    I
    INSM
    2.510
    (3.45%)
    75.330 USD
    REGN
    13.14
    (1.22%)
    1,091.19 USD
الأخبار
المقالات

العنوان: Theravance Biopharma

القطاع: Healthcare
الصناعة: Biotechnology
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).